Glucose and weight control in mice with a designed ghrelin O-acyltransferase inhibitor.

Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Science (Impact Factor: 31.48). 12/2010; 330(6011):1689-92. DOI: 10.1126/science.1196154
Source: PubMed

ABSTRACT Ghrelin is a gastric peptide hormone that stimulates weight gain in vertebrates. The biological activities of ghrelin require octanoylation of the peptide on Ser(3), an unusual posttranslational modification that is catalyzed by the enzyme ghrelin O-acyltransferase (GOAT). Here, we describe the design, synthesis, and characterization of GO-CoA-Tat, a peptide-based bisubstrate analog that antagonizes GOAT. GO-CoA-Tat potently inhibits GOAT in vitro, in cultured cells, and in mice. Intraperitoneal administration of GO-CoA-Tat improves glucose tolerance and reduces weight gain in wild-type mice but not in ghrelin-deficient mice, supporting the concept that its beneficial metabolic effects are due specifically to GOAT inhibition. In addition to serving as a research tool for mapping ghrelin actions, GO-CoA-Tat may help pave the way for clinical targeting of GOAT in metabolic diseases.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Bayliss and Starling first coined the term ‘hormone’ with reference to secretin, a substance they found that was produced by the gut, but released into the blood stream to act at a distance. The intestine is now known as the largest endocrine organ in the body, and it produces numerous hormones with a wide range of functions. These include controlling appetite and energy homeostasis. Obesity is one of the greatest health threats facing the world today. At present, the only successful treatment is surgery. Bariatric procedures such as Roux-en-Y bypass work by elevating gut hormones that induce satiety. Significant research has gone in to producing versions of these hormones that can be delivered therapeutically to treat obesity. This review looks at the role of gut hormones in obesity, and the development of gut hormone-derived obesity treatments.This article is protected by copyright. All rights reserved
    The Journal of Physiology 09/2014; DOI:10.1113/jphysiol.2014.272955 · 4.54 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Nonalcoholic fatty liver disease (NAFLD) is currently considered as the most common liver disease in Western countries, and is rapidly becoming a serious threat to public health worldwide. However, the underlying mechanisms leading to the development of NAFLD are still not fully understood. The ghrelin-ghrelin O-acyltransferase (GOAT) system has recently been found to play a crucial role in both the development of steatosis and its progression to nonalcoholic steatohepatitis. Ghrelin, the natural ligand of the growth hormone secretagogue receptor, is a 28-amino acid peptide possessing a unique acylation on the serine in position 3 catalyzed by GOAT. The ghrelin-GOAT system is involved in insulin resistance, lipid metabolism dysfunction, and inflammation, all of which play important roles in the pathogenesis of NAFLD. A better understanding of ghrelin-GOAT system biology led to the identification of its potential roles in NAFLD. Molecular targets modulating ghrelin-GOAT levels and the biologic effects are being studied, which provide a new insight into the pathogenesis of NAFLD. This review probes into the possible relationship between the ghrelin-GOAT system and NAFLD, and considers the potential mechanisms by which the ghrelin-GOAT system brings about insulin resistance and other aspects concerning NAFLD.
    03/2015; 21(11):3214-3222. DOI:10.3748/wjg.v21.i11.3214
  • [Show abstract] [Hide abstract]
    ABSTRACT: Recent evidence suggests that peripheral ghrelin regulates glucose metabolism. Here, we designed experiments to examine how central acyl ghrelin infusion affects peripheral glucose metabolism under pairfed or ad libitum feeding conditions. Mice received ICV infusion of artificial cerebrospinal fluid (aCSF), ghrelin and allowed to eat ad libitum (icv ghrelin ad-lib) or ghrelin and pairfed to the aCSF group (icv ghrelin pf). Mini pumps delivered acyl ghrelin at a dose of 0.25 μg/hour at 0.5 μl/hour for 7 days. There was no difference in daily blood glucose, insulin, glucagon, triglycerides or non-esterified fatty acids. Body weight gain and food intake was significantly higher in icv ghrelin ad-lib mice, however, both icv ghrelin ad-lib and icv ghrelin pf groups exhibited heavier white adipose mass. Icv ghrelin pf mice exhibited better glucose tolerance than aCSF or icv ghrelin ad-lib mice during a GTT, although both icv ghrelin ad-lib and icv ghrelin pf increased insulin release during the GTT. Central acyl ghrelin infusion and pair feeding also increased breakdown of liver glycogen and triglyceride, and regulated genes involved in hepatic lipid and glucose metabolism. Icv ghrelin pf mice had an increase in plasma blood glucose during a pyruvate tolerance test relative to icv ghrelin ad-lib or aCSF mice. Our results suggest that under conditions of negative energy (icv ghrelin pf) central acyl ghrelin engages a neural circuit that influences hepatic glucose function. Metabolic status affects the ability of central acyl ghrelin to regulate peripheral glucose homeostasis.
    Endocrinology 12/2014; 156(3):en20141733. DOI:10.1210/en.2014-1733 · 4.64 Impact Factor

Full-text (2 Sources)

Available from
May 27, 2014